



The CHEUAL Breast Cancer Model: Interactive Cost-Utility Analysis to Support Decision Making

Transforming Health & Economics 8th World Congress on Health Economics

Assessing Cancer Treatment

<u>Denise Capela dos Santos, PhD</u> Álvaro Lopes Dias, PhD

Toronto, 11st July 2011



Outline of the Presentation

Context
 Challenge
 Research Strategy and Methodology
 CHEUAL BC Model development
 Model Validation
 Summary and reflections

Toronto, 11st July 2011

The CHEUAL BC Model: Interactive Cost-Utility Analysis to Support Decision-Making



Context

Freast cancer is associated with substantial prevalence, incidence, morbidity and mortality.

0,08282% of Portuguese female population has BC (INE, 2005). 0,00962% new BC cases per year (European Observatory of Health, 2008). Female BCRMR was 3,1% of all female number of death (INE, 2009).

\checkmark Huge burden on both individuals and health systems.

Oncology represents the greater costs to the country, with a relative weight of 25,2% of total hospital costs. The major impact on expense was found to be attributable to antineoplasic and imunomodulator therapy, with a burden of 14.269.774€ per month (INFARMED, 2009).

Ministry of Health leads the spending cuts, with a decrease of 7% of the expense from 2010 to 2011 (Portuguese State Budget, 2011).

✓ Multiple alternative approaches to BC treatment.

Aggregate treatment costs will rise quickly even if a treatment at the individual level is perceived to be inexpensive (Karnon & Jones, 2003).


✓ Mathematical modeling makes inferences about future economics and health outcomes to provide data to aid decision-making.

Decisions relating to the allocation of resources in fixed-budget healthcare systems are of extreme importance to cost-containment (ISPOR, 2007).

Toronto, 11st July 2011




Challenge



Toronto, 11st July 2011



Research Strategy and methodology




Primary data: 200 Prescription Charts (most currently used therapy)
Secondary data: Literature review (costs, consequences, other clinical and demographic data)

Toronto, 11st July 2011

The CHEUAL BC Model: Interactive Cost-Utility Analysis to Support Decision-Making



Model development: CHEUAL BC Model design




Toronto, 11st July 2011




Model development: most currently used therapy

Early BC First line therapy (Stages 0, I and II)




Early BC Second line therapy/ Metastatic BC First line therapy (Stage III)



Toronto, 11st July 2011



Model development: complication sub-models



survival


Update simulation data

Toronto, 11st July 2011



Model development:

Markov Process Disease Progression Scheme



Toronto, 11st July 2011

The CHEUAL BC Model: Interactive Cost-Utility Analysis to Support Decision-Making



Model Validation

> Internal validity (inference of causality)

Sensibility Analysis Probabilistic sensibility analysis

> External validity (generalization)

Comparing the results from model simulations with observed outcomes from published epidemiological and clinical studies used and not used to construct the model.


Toronto, 11st July 2011

The CHEUAL BC Model: Interactive Cost-Utility Analysis to Support Decision-Making



Alternative Breast Cancer Pharmacological Treatment

Model Validation: One-way senbibility analysis



Toronto, 11st July 2011



Model Validation:

One-way senbibility analysis results

	Variation (%)	Hypothesis Test	:
Study perspective (NHS, Hospital, Clinical)	2,46	H1 x	
New drug costs* ± 25%	13,52	H2 √	
Personal history of disease (0, 1 or 2)	14,67	H3 √	
Patients age at diagnosis (24-65 or +65)	42,94	H4 √	
Tumor stage (0, I, II, III and IV)	2636,42	H5 √	
Current treatment drug costs* ± 25%	4,34	H6 √	
Global BC costs ± 25%	66,67	H7 √	
Global BC QALYs ± 25%	66,67	H8 √	
Country discount rate (C/QALY: 5%/0% or 5%/5%)	55,13	H9 √	
Study time horizon (5 or 10 years)	101,80	H10 √	
Global complication incidence ± 25%	11,44	H11 √	
ARF ± 25%	0,75	H12 x	
AHF ± 25%	6,06	H13 √	
APD ± 25%	0,87	H14 x	
ACVD ± 25%	0,45	H15 x	
Osteoporosis ± 25%	0,01	H16 x	
AA ± 25%	0,22	H17 x	
AC ± 25%	2,75	H18 √	
AD ± 25%	0,18	H19 x	
*ambulatory day care visit, drug, and drug preparation and administration costs	Exclusion criteria	: Variation $\leq 2,5\%$	

Toronto, 11st July 2011



Summary and Reflections

◆ The CHEUAL BC model allows the identification of efficient BC management strategies and treatments that *are good value for money* in a transparent and efficient way.

◆ Is being adapted to a software, and may be used to other chronicle diseases (especially those with a higher budget impact) and worldwide.

◆ Due to lack of Portuguese data, the model is mainly based on data from clinical studies of other countries, where cultural differences in treatment protocols and differences with exclusion criteria were despised.

◆ The model does not take into account treatments received and healthcare costs incurred early in the course of the disease.

It can also be extended to provide the perspective of society.

◆ This study indicates a step towards the future, although there is still much to be done.

Toronto, 11st July 2011



The CHEUAL Breast Cancer Model: Interactive Cost-Utility Analysis to Support Decision-Making





deniseccsantos@gmail.com www.universidade-autonoma.pt